226 related articles for article (PubMed ID: 35800368)
1. Transcriptional coactivator MED1 in the interface of anti-estrogen and anti-HER2 therapeutic resistance.
Bick G; Zhang J; Lower EE; Zhang X
Cancer Drug Resist; 2022; 5(2):498-510. PubMed ID: 35800368
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor coactivator Mediator Subunit 1 (MED1) as a tissue-specific therapeutic target in breast cancer.
Leonard M; Zhang X
J Zhejiang Univ Sci B; 2019 May; 20(5):381-390. PubMed ID: 31090264
[TBL] [Abstract][Full Text] [Related]
3. HER2-Driven Breast Tumorigenesis Relies upon Interactions of the Estrogen Receptor with Coactivator MED1.
Yang Y; Leonard M; Zhang Y; Zhao D; Mahmoud C; Khan S; Wang J; Lower EE; Zhang X
Cancer Res; 2018 Jan; 78(2):422-435. PubMed ID: 29187405
[TBL] [Abstract][Full Text] [Related]
4. Cross-talk between HER2 and MED1 regulates tamoxifen resistance of human breast cancer cells.
Cui J; Germer K; Wu T; Wang J; Luo J; Wang SC; Wang Q; Zhang X
Cancer Res; 2012 Nov; 72(21):5625-34. PubMed ID: 22964581
[TBL] [Abstract][Full Text] [Related]
5. Overcoming Tamoxifen Resistance of Human Breast Cancer by Targeted Gene Silencing Using Multifunctional pRNA Nanoparticles.
Zhang Y; Leonard M; Shu Y; Yang Y; Shu D; Guo P; Zhang X
ACS Nano; 2017 Jan; 11(1):335-346. PubMed ID: 27966906
[TBL] [Abstract][Full Text] [Related]
6. Role of the Mediator Complex and MicroRNAs in Breast Cancer Etiology.
Maldonado E; Morales-Pison S; Urbina F; Jara L; Solari A
Genes (Basel); 2022 Jan; 13(2):. PubMed ID: 35205279
[TBL] [Abstract][Full Text] [Related]
7. Silencing MED1 sensitizes breast cancer cells to pure anti-estrogen fulvestrant in vitro and in vivo.
Zhang L; Cui J; Leonard M; Nephew K; Li Y; Zhang X
PLoS One; 2013; 8(7):e70641. PubMed ID: 23936234
[TBL] [Abstract][Full Text] [Related]
8. Arginine and glutamate-rich 1 (ARGLU1) interacts with mediator subunit 1 (MED1) and is required for estrogen receptor-mediated gene transcription and breast cancer cell growth.
Zhang D; Jiang P; Xu Q; Zhang X
J Biol Chem; 2011 May; 286(20):17746-54. PubMed ID: 21454576
[TBL] [Abstract][Full Text] [Related]
9. Functional cooperation between co-amplified genes promotes aggressive phenotypes of HER2-positive breast cancer.
Yang Y; Leonard M; Luo Z; Yeo S; Bick G; Hao M; Cai C; Charif M; Wang J; Guan JL; Lower EE; Zhang X
Cell Rep; 2021 Mar; 34(10):108822. PubMed ID: 33691110
[TBL] [Abstract][Full Text] [Related]
10. Med1 plays a critical role in the development of tamoxifen resistance.
Nagalingam A; Tighiouart M; Ryden L; Joseph L; Landberg G; Saxena NK; Sharma D
Carcinogenesis; 2012 Apr; 33(4):918-30. PubMed ID: 22345290
[TBL] [Abstract][Full Text] [Related]
11. Essential role of MED1 in the transcriptional regulation of ER-dependent oncogenic miRNAs in breast cancer.
Nagpal N; Sharma S; Maji S; Durante G; Ferracin M; Thakur JK; Kulshreshtha R
Sci Rep; 2018 Aug; 8(1):11805. PubMed ID: 30087366
[TBL] [Abstract][Full Text] [Related]
12. Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies.
Lousberg L; Collignon J; Jerusalem G
Ther Adv Med Oncol; 2016 Nov; 8(6):429-449. PubMed ID: 27800032
[TBL] [Abstract][Full Text] [Related]
13. MED1/TRAP220 exists predominantly in a TRAP/ Mediator subpopulation enriched in RNA polymerase II and is required for ER-mediated transcription.
Zhang X; Krutchinsky A; Fukuda A; Chen W; Yamamura S; Chait BT; Roeder RG
Mol Cell; 2005 Jul; 19(1):89-100. PubMed ID: 15989967
[TBL] [Abstract][Full Text] [Related]
14. Hyperleptinemia in obese state renders luminal breast cancers refractory to tamoxifen by coordinating a crosstalk between Med1, miR205 and ErbB.
Nagalingam A; Siddharth S; Parida S; Muniraj N; Avtanski D; Kuppusamy P; Elsey J; Arbiser JL; Győrffy B; Sharma D
NPJ Breast Cancer; 2021 Aug; 7(1):105. PubMed ID: 34389732
[TBL] [Abstract][Full Text] [Related]
15. Release of HER2 repression of trefoil factor 3 (TFF3) expression mediates trastuzumab resistance in HER2+/ER+ mammary carcinoma.
Chong QY; You ML; Pandey V; Banerjee A; Chen YJ; Poh HM; Zhang M; Ma L; Zhu T; Basappa S; Liu L; Lobie PE
Oncotarget; 2017 Sep; 8(43):74188-74208. PubMed ID: 29088778
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers.
Nahta R; O'Regan RM
Breast Cancer Res Treat; 2012 Aug; 135(1):39-48. PubMed ID: 22527112
[TBL] [Abstract][Full Text] [Related]
18. Hormonal treatment combined with targeted therapies in endocrine-responsive and HER2-positive metastatic breast cancer.
Montagna E; Colleoni M
Ther Adv Med Oncol; 2019; 11():1758835919894105. PubMed ID: 31897091
[TBL] [Abstract][Full Text] [Related]
19. NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.
Ramos J; Das J; Felty Q; Yoo C; Poppiti R; Murrell D; Foster PJ; Roy D
Breast Cancer Res Treat; 2018 Nov; 172(2):469-485. PubMed ID: 30128822
[TBL] [Abstract][Full Text] [Related]
20. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.
Creighton CJ; Massarweh S; Huang S; Tsimelzon A; Hilsenbeck SG; Osborne CK; Shou J; Malorni L; Schiff R
Cancer Res; 2008 Sep; 68(18):7493-501. PubMed ID: 18794137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
